A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery

Summary

The primary purpose of the study is to compare the effectiveness of nivolumab plus concurrent chemoradiotherapy (CCRT) followed by nivolumab plus ipilimumab vs CCRT followed by durvalumab in participants with untreated Locally Advanced Non-small Cell Lung Cancer (LA NSCLC).

Timeline

Start

2019-10-08

Primary completion

2024-03-22

Completion

2024-11-26

Outcome

Missed primary endpoint

paper At a median follow-up of 30.5 months, there was no statistically significant difference in the primary endpoint of PFS PMID 42129521 ↗

registry Arm A:Nivo + CCRT/Nivo + Ipi vs Arm C: CCRT/Durva; p = 0.6460 NCT04026412 ↗

Publications

• Peters S, Tan DSW, Gerber DE, Urbanic J, Ramalingam S, Yu J, Xing L, Rittmeyer A, Ciuleanu TE, de Menezes J, Kim HR, Rojas C, Syrigos K, Hayashi H, Haridass A, Cortinovis D, Bruno D, Kimmich M, Calles A, Nathani R, Pudussery G, Yang L, De Ruysscher D. Nivolumab plus chemoradiotherapy followed by nivolumab with or without ipilimumab for untreated locally advanced stage III NSCLC: a randomized phase 3 trial. Nat Cancer. 2026 May 13. doi: 10.1038/s43018-026-01161-y. Online ahead of print.
• De Ruysscher D, Ramalingam S, Urbanic J, Gerber DE, Tan DSW, Cai J, Li A, Peters S. CheckMate 73L: A Phase 3 Study Comparing Nivolumab Plus Concurrent Chemoradiotherapy Followed by Nivolumab With or Without Ipilimumab Versus Concurrent Chemoradiotherapy Followed by Durvalumab for Previously Untreated, Locally Advanced Stage III Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2022 May;23(3):e264-e268. doi: 10.1016/j.cllc.2021.07.005. Epub 2021 Jul 19.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Durvalumab	Monoclonal antibody	—	—
Subject	Ipilimumab	Monoclonal antibody	—	—
Subject	Nivolumab	Monoclonal antibody	—	—

Indications